Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Melitracen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 8/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 7/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 6/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.97 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.97 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melitracen SCHEMBL29399425 | 1.00 | HRH1 (0.97) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL2473296 | 1.00 | HRH1 (0.97) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL29195738 | 0.98 | HRH1 (0.94) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL48975 | 0.98 | HRH1 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL29984590 | 0.98 | HRH1 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Melitracen SCHEMBL1650139 | 0.95 | HRH1 (0.94) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Cyclobenzaprine SCHEMBL41376 | 0.77 | LMNA (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Cyclobenzaprine SCHEMBL4964925 | 0.77 | LMNA (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Cyclobenzaprine SCHEMBL29350662 | 0.77 | LMNA (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 | |
| Amitriptyline SCHEMBL14937172 | 0.75 | SLC6A2 (1.00) | HRH1SLC6A2KCNH2HTR2BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| CN-112300119-B | Metliquxin and flupentixol eutectic and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| CN-113677671-B | Eutectic crystal of melitracen and flupentixol and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-114685255-A | Preparation method of melitracen hydrochloride intermediate | 重庆圣华曦药业股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| CN-113105335-B | Synthetic method of stable deuterium-labeled melitracen hydrochloride | 梯尔希（南京）药物研发有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-114057586-A | Melletoxin hydrochloride crystal form A and preparation method thereof | 江苏恩华药业股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113677671-A | Eutectic crystal of melitracen and flupentixol and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2021-11-19 | — | — | CN | claimed |
| CN-109674754-B | Flupentixol and melitracen pharmaceutical composition and preparation thereof | 广东赛烽医药科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-109771386-B | Flupentixol melitracen tablet and preparation method thereof | 广东赛烽医药科技有限公司 | 2021-10-08 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2374450-B1 | Flupentixol compositions | LUNDBECK & CO AS H (DK) | 2012-06-27 | — | — | EP | claimed |
| EP-2374450-A1 | Flupentixol compositions | H. Lundbeck A/S (DK) | 2011-10-12 | — | — | EP | claimed |
| CN-101912397-A | Flupentixol composition | LUNDBECK & CO AS H | 2010-12-15 | — | — | CN | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307386-A1 | NOVEL METHODS | OPRL1, HTR2A, OPRM1 | HRH1 701/4885SLC6A2 174/4885KCNH2 4441/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | HRH1 255/4885SLC6A2 44/4885KCNH2 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.